The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders
Open accessAbstract
Background & aims There are few effective treatments for nausea and other symptoms in patients with gastroparesis and related syndromes. We performed a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome. Methods We conducted a 4-week multicenter, double-masked trial of 126 patients with at least moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 months. Patients were randomly assigned to groups given oral aprepitant (125 mg/day, n = 63) or placebo (n = 63). The primary outcome from the intention-to-treat analysis was reduction in nausea, defined as a decrease of 25 mm or more, or absolute level below 25 mm, on a daily patient-reported 0-to-100 visual analog scale (VAS) of nausea severity. We calculated relative risks of nausea improvement using stratified Cochran-Mental-Haenszel analysis. Results Aprepitant did not reduce symptoms of nausea, based on the primary outcome measure (46% reduction in the VAS score in the aprepitant group vs 40% reduction in the placebo group; relative risk, 1.2; 95% CI, 0.8-1.7) (P = .43). However, patients in the aprepitant group had significant changes in secondary outcomes such as reduction in symptom severity (measured by the 0-5 Gastroparesis Clinical Symptom Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1.3 vs 0.7; P = .001). Adverse events, predominantly mild or moderate in severity grade, were more common in aprepitant (22 of 63 patients, 35% vs 11 of 63, 17% in the placebo group) (P = .04). Conclusions In a randomized trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome, aprepitant did not reduce the severity of nausea when reduction in VAS score was used as the primary outcome. However, aprepitant had varying effects on secondary outcomes of symptom improvement. These findings support the need to identify appropriate patient outcomes for trials of therapies for gastroparesis, including potential additional trials for aprepitant. ClinicalTrials.gov no: NCT01149369.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a 4‐week, multicenter, randomized double‐masked trial of 126 adults with gastroparesis (and related syndromes), although oral aprepitant (125 mg) failed to significantly reduce nausea when measured by visual analog criteria, it achieved the secondary outcomes of significant reduction in nausea and vomiting severity index as measured by the Gastroparesis Clinical Symptom Index.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Svedlund, J., Sjödin, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,319
Assessment of gastric emptying using a low fat meal: establishment of international control values
Tougas, G. H., Eaker, E. Y., Abell, T. L., Abrahamsson, H., Boivin, M., Chen, J. D. Z., Hocking, M. P., Quigley, E. M. M., Koch, K. L., Tokayer, A., et al. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02076.x · Cited by 676
Self-citationWarr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., Raftopoulos, H., Grunberg, S. M., Gabriel, M., Rodgers, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.050 · Cited by 464
NK1 (substance P) receptor antagonists – why are they not analgesic in humans?
Hill, R. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01502-9 · Cited by 462
Rentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406
Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P. J., Stanghellini, V., Talley, N. J., & Tack, J. F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01612.x · Cited by 382
Parkman, H. P., Yates, K. P., Hasler, W. L., Nguyen, L. A. B., Pasricha, P. J., Snape, W. J., Farrugia, G., Koch, K. L., Abell, T. L., McCallum, R. W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.015 · Cited by 348
Self-citationCharacteristics of Patients With Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying
Pasricha, P. J., Colvin, R., Yates, K. P., Hasler, W. L., Abell, T. L., Ünalp–Arida, A., Nguyen, L. A. B., Farrugia, G., Koch, K. L., Parkman, H. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.003 · Cited by 247
Self-citationBrown, J., Liu, H., Maggio, J. E., Vigna, S. R., Mantyh, P. W., & Basbaum, A. I. (1995) · The Journal of Comparative Neurology · doi:10.1002/cne.903560302 · Cited by 240
Gan, T. J., Apfel, C. C., Kovac, A. L., Philip, B. K., Singla, N., Minkowitz, H. S., Habib, A. S., Knighton, J., Carides, A. D., Zhang, H., et al. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000263277.35140.a3 · Cited by 223
Flagged first, then by citations
Cited by
Sorted by citations
Camilleri, M., Chedid, V., Ford, A. C., Haruma, K., Horowitz, M., Jones, K. L., Low, P. A., Park, S.-Y., Parkman, H. P., & Stanghellini, V. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0038-z · Cited by 411
Self-citationACG Clinical Guideline: Gastroparesis
Camilleri, M., Kuo, B., Nguyen, L., Vaughn, V. M., Petrey, J., Greer, K., Yadlapati, R., & Abell, T. L. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001874 · Cited by 332
Self-citationGastroparesis: a turning point in understanding and treatment
Grover, M., Farrugia, G., & Stanghellini, V. (2019) · Gut · doi:10.1136/gutjnl-2019-318712 · Cited by 256
Self-citationBharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
British Society of Gastroenterology guidelines on the management of functional dyspepsia
Black, C. J., Paine, P., Agrawal, A., Aziz, I., Eugenicos, M. P., Houghton, L. A., Hungin, P., Overshott, R., Vasant, D. H., Rudd, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327737 · Cited by 216
Metadata
- Authors
- Pasricha, P. J., Yates, K. P., Sarosiek, I., McCallum, R. W., Abell, T. L., Koch, K. L., Nguyen, L. A. B., Snape, W. J., Hasler, W. L., Clarke, J. O., Dhalla, S., Stein, E. M., Lee, L. A., Miriel, L. A., Van Natta, M. L., Grover, M., Farrugia, G., Tonascia, J., Hamilton, F. A., Parkman, H. P., Snape, W. J., DeVole, N., Earle, K., Kirkeby, K., Lee, C., Lin, M., Ponting, K., Yee, G., Pasricha, P. J., Clarke, J. O., Stein, E., Dhalla, S., Kim, Y., Nguyen, L. A. B., Garay, G., Orlando, C., Parkman, H. P., Mauer, A., Orthey, P., Palit, A., McCallum, R. W., Sarosiek, I., Connery, S., Gomez, Y., Romero, R., Vega, N., Alvarado, B., Abell, T. L., Hatter, L., Howard, R., Nowotny, L., Hasler, W. L., Herman, W., Kraftson, A., Rothberg, A. E., Wootten, S., Koch, K. L., Baxter, L., Brown, A., Stuart, P., Culler, S., Farrugia, G., Grover, M., Bernard, C., Hamilton, F., Serrano, J., James, S., Torrance, R., Hall, S., Tonascia, J., Belt, P., Dodge, J., Donithan, M., Hallinan, E., Isaacson, M., Lee, L. A., May, P. K., Miriel, L., Sternberg, A., Van Natta, M., Wagoner, A., Wilson, L., & Yates, K. P.
- Affiliations
- Johns Hopkins University (US)
- Michigan Medicine (US)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 154
- Issue
- 1
- Pages
- 65-76.e11
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC5742047
- OpenAlex
- W2766218920
- Cited by
- 143
- References
- 35
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 16 · 2022: 18 · 2021: 22 · 2020: 19 · 2019: 25 · 2018: 16
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR001105, UL1TR000135, UL1TR000433, UL1TR000424)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK074008, U01DK073985, K23DK103911, U24DK074008, U01DK073974, U01DK074007, U01DK112193, U01DK073983, U01DK073975, U01DK074035)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- aprepitant, gastroparesis, chronic nausea, vomiting, NK1 receptor antagonists, symptom severity, adverse events, nausea severity
- MeSH terms
- Aprepitant, Adult, Antiemetics, Chronic Disease, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Nausea, Vomiting, Treatment Outcome, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review